QCG
RDY icon

Quadrant Capital Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Quadrant Capital Group’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.78M Buy
489,799
+306,046
+167% +$4.26M 0.2% 64
2025
Q4 		$2.58M Sell
183,753
-227,621
-55% -$3.19M 0.08% 201
2025
Q3 		$5.75M Buy
411,374
+145,259
+55% +$2.09M 0.19% 71
2025
Q2 		$4M Buy
266,115
+111,068
+72% +$1.59M 0.14% 110
2025
Q1 		$2.05M Sell
155,047
-16,962
-10% -$234K 0.08% 183
2024
Q4 		$2.72M Buy
172,009
+11,394
+7% +$171K 0.19% 65
2024
Q3 		$2.55M Buy
160,615
+5,900
+4% +$94.9K 0.18% 72
2024
Q2 		$2.36M Buy
154,715
+3,820
+3% +$54.8K 0.18% 74
2024
Q1 		$2.21M Buy
150,895
+8,795
+6% +$128K 0.17% 78
2023
Q4 		$1.98M Buy
142,100
+24,710
+21% +$330K 0.17% 84
2023
Q3 		$1.57M Buy
117,390
+5,555
+5% +$75.2K 0.16% 89
2023
Q2 		$1.41M Buy
111,835
+5,075
+5% +$59.2K 0.14% 99
2023
Q1 		$1.22M Buy
106,760
+35,530
+50% +$384K 0.13% 112
2022
Q4 		$737K Buy
71,230
+16,055
+29% +$173K 0.08% 177
2022
Q3 		$578K Buy
55,175
+16,125
+41% +$172K 0.08% 187
2022
Q2 		$433K Buy
39,050
+10,320
+36% +$112K 0.06% 245
2022
Q1 		$321K Buy
28,730
+7,835
+37% +$88.8K 0.04% 330
2021
Q4 		$273K Buy
20,895
+3,040
+17% +$38.3K 0.03% 357
2021
Q3 		$233K Buy
17,855
+1,935
+12% +$25.8K 0.03% 351
2021
Q2 		$234K Buy
15,920
+2,875
+22% +$40.2K 0.03% 344
2021
Q1 		$160K Buy
13,045
+645
+5% +$8.29K 0.03% 414
2020
Q4 		$177K Buy
12,400
+710
+6% +$9.56K 0.03% 336
2020
Q3 		$163K Buy
11,690
+3,170
+37% +$37.8K 0.04% 305
2020
Q2 		$90K Sell
8,520
-88,695
-91% -$902K 0.02% 488
2020
Q1 		$786K Buy
97,215
+28,650
+42% +$239K 0.13% 131
2019
Q4 		$550K Buy
68,565
+5,425
+9% +$42.8K 0.07% 267
2019
Q3 		$475K Buy
63,140
+7,085
+13% +$52.7K 0.07% 264
2019
Q2 		$415K Sell
56,055
-9,295
-14% -$73.1K 0.07% 289
2019
Q1 		$526K Buy
65,350
+31,360
+92% +$238K 0.09% 187
2018
Q4 		$252K Buy
33,990
+31,380
+1,202% +$221K 0.07% 267
2018
Q3 		$16K Sell
2,610
-770
-23% -$5.15K ﹤0.01% 1089
2018
Q2 		$19K Buy
3,380
+1,850
+121% +$11.7K 0.01% 1000
2018
Q1 		$8K Buy
1,530
+240
+19% +$1.68K ﹤0.01% 1365
2017
Q4 		$8K Buy
1,290
+875
+211% +$6.3K ﹤0.01% 1289
2017
Q3 		$2K Sell
415
-685
-62% -$4.92K ﹤0.01% 1829
2017
Q2 		$6K Buy
1,100
+115
+12% +$935 ﹤0.01% 1294
2017
Q1 		$6K Hold
985
– – ﹤0.01% 1279
2016
Q4 		$7K Hold
985
– – ﹤0.01% 1149
2016
Q3 		$8K Buy
985
+865
+721% +$8.26K 0.01% 1127
2016
Q2 		$1K Sell
120
-225
-65% -$2.06K ﹤0.01% 1732
2016
Q1 		$2K Buy
+345
New +$3.08K ﹤0.01% 1377
2015
Q4 		– Sell
-125
Closed -$1K – 1675
2015
Q3 		$1K Hold
125
– – ﹤0.01% 1102
2015
Q2 		$1K Buy
+125
New +$1.38K ﹤0.01% 1083

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Quadrant Capital Group's RDY Position: Q1 2026 in Review

Quadrant Capital Group increased its Dr. Reddy's Laboratories (RDY) stake by 167% in Q1 2026, buying an estimated $4.26M and bringing the position to 489,799 shares worth $6.78M. The position accounts for 0.2% of the portfolio, ranked #64.

Quadrant Capital Group first reported a position in RDY in Q2 2015 and has held it in 43 quarters since. 247 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Quadrant Capital Group held 489,799 shares of Dr. Reddy's Laboratories worth $6.78M as of Q1 2026.
  • Quadrant Capital Group bought 306,046 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $4.26M.
  • Dr. Reddy's Laboratories made up 0.2% of Quadrant Capital Group's portfolio in Q1 2026, its #64 holding.
  • Quadrant Capital Group first reported a position in Dr. Reddy's Laboratories in Q2 2015 and has held it in 43 quarters since.
  • 247 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.